JPWO2006126488A1 - Hanabira bamboo extract - Google Patents
Hanabira bamboo extract Download PDFInfo
- Publication number
- JPWO2006126488A1 JPWO2006126488A1 JP2007517815A JP2007517815A JPWO2006126488A1 JP WO2006126488 A1 JPWO2006126488 A1 JP WO2006126488A1 JP 2007517815 A JP2007517815 A JP 2007517815A JP 2007517815 A JP2007517815 A JP 2007517815A JP WO2006126488 A1 JPWO2006126488 A1 JP WO2006126488A1
- Authority
- JP
- Japan
- Prior art keywords
- extract
- molecular weight
- hanabiratake
- component
- antitumor
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000000284 extract Substances 0.000 title claims abstract description 70
- 235000017166 Bambusa arundinacea Nutrition 0.000 title claims description 19
- 235000017491 Bambusa tulda Nutrition 0.000 title claims description 19
- 241001330002 Bambuseae Species 0.000 title claims description 19
- 235000015334 Phyllostachys viridis Nutrition 0.000 title claims description 19
- 239000011425 bamboo Substances 0.000 title claims description 19
- 230000000259 anti-tumor effect Effects 0.000 claims abstract description 33
- 239000000203 mixture Substances 0.000 claims abstract description 23
- 239000004480 active ingredient Substances 0.000 claims abstract description 15
- 235000013402 health food Nutrition 0.000 claims abstract description 13
- 239000002537 cosmetic Substances 0.000 claims abstract description 12
- 239000002246 antineoplastic agent Substances 0.000 claims abstract description 10
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims description 34
- 239000002904 solvent Substances 0.000 claims description 22
- 238000000502 dialysis Methods 0.000 claims description 17
- 239000012528 membrane Substances 0.000 claims description 16
- 229920002498 Beta-glucan Polymers 0.000 claims description 13
- FYGDTMLNYKFZSV-URKRLVJHSA-N (2s,3r,4s,5s,6r)-2-[(2r,4r,5r,6s)-4,5-dihydroxy-2-(hydroxymethyl)-6-[(2r,4r,5r,6s)-4,5,6-trihydroxy-2-(hydroxymethyl)oxan-3-yl]oxyoxan-3-yl]oxy-6-(hydroxymethyl)oxane-3,4,5-triol Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@H]1OC1[C@@H](CO)O[C@@H](OC2[C@H](O[C@H](O)[C@H](O)[C@H]2O)CO)[C@H](O)[C@H]1O FYGDTMLNYKFZSV-URKRLVJHSA-N 0.000 claims description 12
- 238000002523 gelfiltration Methods 0.000 claims description 6
- 238000012869 ethanol precipitation Methods 0.000 claims description 4
- 235000009499 Vanilla fragrans Nutrition 0.000 claims 1
- 244000263375 Vanilla tahitensis Species 0.000 claims 1
- 235000012036 Vanilla tahitensis Nutrition 0.000 claims 1
- 235000013399 edible fruits Nutrition 0.000 abstract description 29
- 235000001674 Agaricus brunnescens Nutrition 0.000 abstract description 8
- 210000001035 gastrointestinal tract Anatomy 0.000 abstract description 6
- 239000000843 powder Substances 0.000 abstract description 5
- 235000004611 garlic Nutrition 0.000 abstract description 4
- 244000245420 ail Species 0.000 abstract 1
- 230000000144 pharmacologic effect Effects 0.000 abstract 1
- 238000000638 solvent extraction Methods 0.000 abstract 1
- 239000000306 component Substances 0.000 description 49
- 238000000034 method Methods 0.000 description 17
- 238000000605 extraction Methods 0.000 description 12
- 239000000047 product Substances 0.000 description 11
- 238000004519 manufacturing process Methods 0.000 description 10
- 210000004027 cell Anatomy 0.000 description 9
- 239000006228 supernatant Substances 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 206010028980 Neoplasm Diseases 0.000 description 7
- 150000003384 small molecules Chemical class 0.000 description 7
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 5
- 238000009826 distribution Methods 0.000 description 5
- 230000000694 effects Effects 0.000 description 5
- 238000005194 fractionation Methods 0.000 description 5
- 239000002609 medium Substances 0.000 description 5
- 238000001228 spectrum Methods 0.000 description 5
- 238000010521 absorption reaction Methods 0.000 description 4
- 230000010261 cell growth Effects 0.000 description 4
- 238000005119 centrifugation Methods 0.000 description 4
- IQFVPQOLBLOTPF-HKXUKFGYSA-L congo red Chemical compound [Na+].[Na+].C1=CC=CC2=C(N)C(/N=N/C3=CC=C(C=C3)C3=CC=C(C=C3)/N=N/C3=C(C4=CC=CC=C4C(=C3)S([O-])(=O)=O)N)=CC(S([O-])(=O)=O)=C21 IQFVPQOLBLOTPF-HKXUKFGYSA-L 0.000 description 4
- -1 corrigents Substances 0.000 description 4
- 235000013305 food Nutrition 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000002244 precipitate Substances 0.000 description 4
- 238000002360 preparation method Methods 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 230000004614 tumor growth Effects 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- 240000002234 Allium sativum Species 0.000 description 3
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 3
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 3
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 3
- 241000218652 Larix Species 0.000 description 3
- 235000005590 Larix decidua Nutrition 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 3
- 230000005907 cancer growth Effects 0.000 description 3
- 230000000052 comparative effect Effects 0.000 description 3
- 239000012153 distilled water Substances 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 239000007788 liquid Substances 0.000 description 3
- 239000000463 material Substances 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 3
- 239000008363 phosphate buffer Substances 0.000 description 3
- 239000011148 porous material Substances 0.000 description 3
- 239000002994 raw material Substances 0.000 description 3
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 2
- 241000222518 Agaricus Species 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 description 2
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 2
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 description 2
- 229920002307 Dextran Polymers 0.000 description 2
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 2
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 description 2
- 229920005654 Sephadex Polymers 0.000 description 2
- 239000012507 Sephadex™ Substances 0.000 description 2
- XSQUKJJJFZCRTK-UHFFFAOYSA-N Urea Chemical compound NC(N)=O XSQUKJJJFZCRTK-UHFFFAOYSA-N 0.000 description 2
- RJURFGZVJUQBHK-UHFFFAOYSA-N actinomycin D Natural products CC1OC(=O)C(C(C)C)N(C)C(=O)CN(C)C(=O)C2CCCN2C(=O)C(C(C)C)NC(=O)C1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)NC4C(=O)NC(C(N5CCCC5C(=O)N(C)CC(=O)N(C)C(C(C)C)C(=O)OC4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-UHFFFAOYSA-N 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 244000309464 bull Species 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 229910052799 carbon Inorganic materials 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 238000012790 confirmation Methods 0.000 description 2
- 238000007796 conventional method Methods 0.000 description 2
- 238000012258 culturing Methods 0.000 description 2
- 238000001514 detection method Methods 0.000 description 2
- 229940079593 drug Drugs 0.000 description 2
- 239000000796 flavoring agent Substances 0.000 description 2
- 235000013312 flour Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000020710 ginseng extract Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 235000011187 glycerol Nutrition 0.000 description 2
- 230000012010 growth Effects 0.000 description 2
- 230000014759 maintenance of location Effects 0.000 description 2
- 235000015097 nutrients Nutrition 0.000 description 2
- 125000001477 organic nitrogen group Chemical group 0.000 description 2
- 238000002054 transplantation Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- 239000003643 water by type Substances 0.000 description 2
- WDQLRUYAYXDIFW-RWKIJVEZSA-N (2r,3r,4s,5r,6r)-4-[(2s,3r,4s,5r,6r)-3,5-dihydroxy-4-[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxy-6-[[(2r,3r,4s,5s,6r)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxymethyl]oxan-2-yl]oxy-6-(hydroxymethyl)oxane-2,3,5-triol Chemical compound O[C@@H]1[C@@H](CO)O[C@@H](O)[C@H](O)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)[C@H](O)[C@@H](CO[C@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)O)O1 WDQLRUYAYXDIFW-RWKIJVEZSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- 229920001817 Agar Polymers 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 229920001661 Chitosan Polymers 0.000 description 1
- 206010009944 Colon cancer Diseases 0.000 description 1
- 108010092160 Dactinomycin Proteins 0.000 description 1
- 241000238557 Decapoda Species 0.000 description 1
- 239000004375 Dextrin Substances 0.000 description 1
- 229920001353 Dextrin Polymers 0.000 description 1
- 241000233866 Fungi Species 0.000 description 1
- 241000222336 Ganoderma Species 0.000 description 1
- 240000008397 Ganoderma lucidum Species 0.000 description 1
- 235000001637 Ganoderma lucidum Nutrition 0.000 description 1
- 206010053759 Growth retardation Diseases 0.000 description 1
- 241001632576 Hyacinthus Species 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 1
- 229920001491 Lentinan Polymers 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699670 Mus sp. Species 0.000 description 1
- 240000008790 Musa x paradisiaca Species 0.000 description 1
- 241000237524 Mytilus Species 0.000 description 1
- 244000170916 Paeonia officinalis Species 0.000 description 1
- 235000006484 Paeonia officinalis Nutrition 0.000 description 1
- 239000001888 Peptone Substances 0.000 description 1
- 108010080698 Peptones Proteins 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000006146 Roswell Park Memorial Institute medium Substances 0.000 description 1
- 206010039491 Sarcoma Diseases 0.000 description 1
- 229920002305 Schizophyllan Polymers 0.000 description 1
- 239000012506 Sephacryl® Substances 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
- 229930006000 Sucrose Natural products 0.000 description 1
- 244000085595 Zizania latifolia Species 0.000 description 1
- 235000004259 Zizania latifolia Nutrition 0.000 description 1
- RJURFGZVJUQBHK-IIXSONLDSA-N actinomycin D Chemical compound C[C@H]1OC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C(=O)[C@@H]2CCCN2C(=O)[C@@H](C(C)C)NC(=O)[C@H]1NC(=O)C1=C(N)C(=O)C(C)=C2OC(C(C)=CC=C3C(=O)N[C@@H]4C(=O)N[C@@H](C(N5CCC[C@H]5C(=O)N(C)CC(=O)N(C)[C@@H](C(C)C)C(=O)O[C@@H]4C)=O)C(C)C)=C3N=C21 RJURFGZVJUQBHK-IIXSONLDSA-N 0.000 description 1
- 239000008272 agar Substances 0.000 description 1
- 150000001298 alcohols Chemical class 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- 239000002260 anti-inflammatory agent Substances 0.000 description 1
- 229940121363 anti-inflammatory agent Drugs 0.000 description 1
- 239000012298 atmosphere Substances 0.000 description 1
- 235000021015 bananas Nutrition 0.000 description 1
- 235000013361 beverage Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000012888 bovine serum Substances 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940041514 candida albicans extract Drugs 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 239000004202 carbamide Substances 0.000 description 1
- 150000001720 carbohydrates Chemical class 0.000 description 1
- 239000001569 carbon dioxide Substances 0.000 description 1
- 229910002092 carbon dioxide Inorganic materials 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 238000010609 cell counting kit-8 assay Methods 0.000 description 1
- 239000003153 chemical reaction reagent Substances 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 208000029742 colonic neoplasm Diseases 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 235000009508 confectionery Nutrition 0.000 description 1
- 235000014510 cooky Nutrition 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 238000012364 cultivation method Methods 0.000 description 1
- 229960000640 dactinomycin Drugs 0.000 description 1
- 235000019425 dextrin Nutrition 0.000 description 1
- 239000000385 dialysis solution Substances 0.000 description 1
- 235000013325 dietary fiber Nutrition 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 239000003995 emulsifying agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 235000013355 food flavoring agent Nutrition 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 230000002538 fungal effect Effects 0.000 description 1
- 239000011521 glass Substances 0.000 description 1
- 239000008187 granular material Substances 0.000 description 1
- 239000003102 growth factor Substances 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 1
- 229910000041 hydrogen chloride Inorganic materials 0.000 description 1
- 230000005965 immune activity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000011081 inoculation Methods 0.000 description 1
- 239000002054 inoculum Substances 0.000 description 1
- 229910052742 iron Inorganic materials 0.000 description 1
- 235000015110 jellies Nutrition 0.000 description 1
- 239000008274 jelly Substances 0.000 description 1
- 239000008101 lactose Substances 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940115286 lentinan Drugs 0.000 description 1
- 208000032839 leukemia Diseases 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 238000009630 liquid culture Methods 0.000 description 1
- 230000005923 long-lasting effect Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 239000012533 medium component Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000003020 moisturizing effect Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000003921 oil Substances 0.000 description 1
- 229920001542 oligosaccharide Polymers 0.000 description 1
- 150000002482 oligosaccharides Chemical class 0.000 description 1
- 230000003647 oxidation Effects 0.000 description 1
- 238000007254 oxidation reaction Methods 0.000 description 1
- 238000012856 packing Methods 0.000 description 1
- 235000019319 peptone Nutrition 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 239000000419 plant extract Substances 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 108010001062 polysaccharide-K Proteins 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 238000011002 quantification Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 239000012679 serum free medium Substances 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 239000005720 sucrose Substances 0.000 description 1
- 239000004094 surface-active agent Substances 0.000 description 1
- 239000000375 suspending agent Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 238000013268 sustained release Methods 0.000 description 1
- 239000012730 sustained-release form Substances 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000008399 tap water Substances 0.000 description 1
- 235000020679 tap water Nutrition 0.000 description 1
- 239000002562 thickening agent Substances 0.000 description 1
- 230000036962 time dependent Effects 0.000 description 1
- 239000011573 trace mineral Substances 0.000 description 1
- 235000013619 trace mineral Nutrition 0.000 description 1
- 210000004881 tumor cell Anatomy 0.000 description 1
- 239000006097 ultraviolet radiation absorber Substances 0.000 description 1
- 238000003809 water extraction Methods 0.000 description 1
- 230000002087 whitening effect Effects 0.000 description 1
- 239000012138 yeast extract Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
- A61K36/06—Fungi, e.g. yeasts
- A61K36/07—Basidiomycota, e.g. Cryptococcus
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L31/00—Edible extracts or preparations of fungi; Preparation or treatment thereof
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L5/00—Preparation or treatment of foods or foodstuffs, in general; Food or foodstuffs obtained thereby; Materials therefor
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/96—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution
- A61K8/97—Cosmetics or similar toiletry preparations characterised by the composition containing materials, or derivatives thereof of undetermined constitution from algae, fungi, lichens or plants; from derivatives thereof
- A61K8/9728—Fungi, e.g. yeasts
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Natural Medicines & Medicinal Plants (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Biotechnology (AREA)
- Epidemiology (AREA)
- Nutrition Science (AREA)
- Botany (AREA)
- Food Science & Technology (AREA)
- Polymers & Plastics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Medical Informatics (AREA)
- Alternative & Traditional Medicine (AREA)
- Birds (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Medicines Containing Plant Substances (AREA)
- Cosmetics (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
優れた薬理活性を有し、消化管から吸収され易い比較的低分子量の抗腫瘍成分、ならびに、その成分を有効成分とする抗腫瘍剤、化粧品及び健康食品を提供する。ハナビラタケの子実体又は菌糸体を凍結乾燥の後、微粉末化し、その粉末を溶媒抽出処理し、抽出物を分画処理することにより得られる分子量が５００〜１００００の範囲内の成分を主成分として含有するハナビラタケ抽出物組成物及びそれを有効成分とする抗腫瘍性組成物、化粧品及び健康食品。Provided are an antitumor component having a relatively low molecular weight that has excellent pharmacological activity and is easily absorbed from the digestive tract, and an antitumor agent, cosmetics, and health food containing the component as an active ingredient. The fruit body or mycelium of garlic mushroom is freeze-dried and then pulverized, the powder is subjected to solvent extraction treatment, and the extract is fractionated to obtain a component having a molecular weight in the range of 500 to 10,000 as a main component. Containing Hanabiratake extract composition, antitumor composition, cosmetic and health food containing the composition as an active ingredient.
Description
本発明は、ハナビラタケの子実体又は菌糸体から得られる比較的低分子量の成分を主成分とするハナビラタケ抽出物並びにそれを有効成分として含有する抗腫瘍剤、化粧品及び健康食品に関するものである。 The present invention relates to an extract of Hanabira bamboo mainly composed of a relatively low molecular weight component obtained from the fruit body or mycelium of Hanabira bamboo, and an antitumor agent, a cosmetic and a health food containing the same as an active ingredient.
キノコ類は古くから食用として利用されているが、近年、その成分の生理活性が明らかにされてきている。なかでも、クレスチン、レンチナン、シゾフィラン（いずれも商品名）等は、医薬品としてその有用性が認められおり、また、アガリクス、メシマコブ、霊芝等は免疫賦活作用や抗腫瘍作用を期待して、子実体や菌糸体の乾燥物あるいは抽出物を健康食品素材として利用することが試みられている。例えば、マンネンタケは、子実体又はその抽出物を健康食品の原料として利用することが試みられている（例えば、特許文献１、２及び３参照）。 Mushrooms have been used for food since ancient times, but in recent years, the physiological activity of the components has been clarified. Among them, krestin, lentinan, and schizophyllan (all trade names) are recognized as useful drugs, and agaricus, mesimacob, ganoderma, etc. Attempts have been made to use dried or extracted substances or mycelia as health food materials. For example, Mannentake has been tried to use fruit bodies or extracts thereof as raw materials for health foods (see, for example, Patent Documents 1, 2, and 3).
一方、これらキノコ類に属するハナビラタケ（Ｓｐａｒａｓｓｉｓ ｃｒｉｓｐａ）は、カラマツ等に生えるキノコであって、歯ごたえが良く、その純白な色合いと葉牡丹のような形態が特徴である、非常に僅少な食用キノコである。これまで、このハナビラタケは成長が遅く人工栽培は非常に困難であるとされてきたが、近年、比較的短期間で栽培可能な新しい栽培方法が確立され、商業規模での供給が可能となっている（例えば、特許文献４及び５参照）。 On the other hand, Hanabiratake (Sparasis crispa) belonging to these mushrooms is a very small edible mushroom that grows in larch etc., has a good texture and is characterized by its pure white color and leafy peony. . Up until now, it has been said that this bamboo shoot has slow growth and is extremely difficult to cultivate artificially. (For example, see Patent Documents 4 and 5).
そのハナビラタケの子実体は、抗腫瘍活性を有することがこれまでに明らかになっている（例えば、非特許文献１、２参照）。そして、その有効成分は、ハナビラタケの乾燥重量の４０〜５０％程度を占めるβ−１，３−グルカンであるといわれている（例えば、特許文献６参照）。
キノコ類の抗腫瘍活性の主体とされていたβグルカンについては、分子量が数百万程度と大きく、一般的には必ずしも消化管からの吸収が良いとはいえない。そこで、より低分子で消化管からの吸収が良好な抗腫瘍成分が強く望まれていた。 Β-glucan, which has been regarded as the main antitumor activity of mushrooms, has a large molecular weight of about several millions and is generally not necessarily well absorbed from the digestive tract. Therefore, an antitumor component having a lower molecular weight and good absorption from the gastrointestinal tract has been strongly desired.
本発明は、ハナビラタケ子実体又は菌糸体由来の低分子抗腫瘍成分並びにそれを有効成分とする抗腫瘍剤、化粧品及び健康食品を提供することを目的とするものである。 An object of the present invention is to provide a low molecular weight antitumor component derived from a fruit body or a mycelium of an alga, and an antitumor agent, a cosmetic and a health food containing the same as an active ingredient.
本発明者らは、上記課題を達成するために鋭意検討を重ねた結果、ハナビラタケの子実体又は菌糸体の溶媒抽出物より得られる、βグルカンをほとんど含有しない低分子成分が良好な抗腫瘍活性を有することを見出し、本発明に至った。 As a result of intensive studies to achieve the above-mentioned problems, the present inventors have obtained a low molecular weight component containing almost no β-glucan, which is obtained from a fruit extract or a mycelium extract of Hanabiratake, and has a good antitumor activity. As a result, the present invention was reached.
すなわち、本発明は、ハナビラタケの溶媒抽出物であって、主成分が分子量５００〜１００００の範囲内の成分であるハナビラタケ抽出物を要旨とするものであり、別の発明は、ハナビラタケの溶媒抽出物から、透析膜を用いて主成分が分子量５００〜１００００の範囲内の成分を分画して得られるハナビラタケ抽出物を要旨とするものであり、また別の発明は、ハナビラタケの溶媒抽出物から、ゲル濾過法により主成分が分子量５００〜１００００の範囲内の成分を分画して得られるハナビラタケ抽出物を要旨とするものであり、また別の発明は、ハナビラタケの溶媒抽出物から、エタノール沈澱を行なうことにより主成分が分子量５００〜１００００の範囲内の成分を分画して得られるハナビラタケ抽出物を要旨とするものである。また他の発明は、前記したハナビラタケ抽出物を有効成分として含有する抗腫瘍剤を要旨とするものであり、また別の発明は前記したハナビラタケ抽出物を有効成分として含有する化粧品を要旨とするものであり、さらに別の発明は前記したハナビラタケ抽出物を有効成分として含有する健康食品を要旨とするものである。
本発明は、上記ハナビラタケの溶媒抽出物を対象に投与することによる腫瘍の治療方法または腫瘍細胞の増殖抑制方法も提供し、さらに、抗腫瘍剤の製造のための上記ハナビラタケの溶媒抽出物の使用も提供する。That is, the present invention is a solvent extract of Hanabiratake, the main component of which is a component having a molecular weight in the range of 500 to 10,000, and another invention is a solvent extract of Hanabiratake. In addition, the ginseng extract is obtained by fractionating components having a molecular weight of 500 to 10,000 using a dialysis membrane, and another invention is based on the solvent extract of Hanabiratake, The gist of the present invention is that of an extract of Hanabiratake obtained by fractionating components having a molecular weight of 500 to 10,000 by gel filtration, and another invention relates to ethanol precipitation from a solvent extract of Hanabiratake. A ginseng extract obtained by fractionating a component having a molecular weight of 500 to 10,000 as a main component by carrying out the present invention. Another aspect of the invention is a gist of an antitumor agent containing the above-mentioned Hanabiratake extract as an active ingredient, and another invention is a gist of a cosmetic containing the above-mentioned Hanabiratake extract as an active ingredient. Yet another invention is summarized as a health food containing the above-mentioned Hanabiratake extract as an active ingredient.
The present invention also provides a method for treating a tumor or a method for inhibiting the growth of tumor cells by administering the above-mentioned solvent extract of Hanabiratake to a subject, and further uses the solvent extract of Hanabiratake for the production of an antitumor agent. Also provide.
本発明によれば、分子量が５００〜１００００の範囲の低分子成分であるため、経口投与した場合に消化管からの吸収に優れ、その結果抗腫瘍活性が向上するという効果を奏する。 According to the present invention, since it is a low molecular weight component having a molecular weight in the range of 500 to 10,000, when administered orally, it is excellent in absorption from the gastrointestinal tract, resulting in an effect of improving antitumor activity.
以下、本発明を詳細に説明する。 Hereinafter, the present invention will be described in detail.
ハナビラタケは、標高１０００メートル以上のカラマツ等の針葉樹林に特異的に発生するキノコであり、発見することが困難なために「幻のキノコ」と言われてきた。これまで、その栽培は難しく、一般にはあまり知られていなかったが、近年、人工栽培方法が確立され、量産が可能となった。 Hanabiratake is a mushroom that occurs specifically in coniferous forests such as larch at an altitude of 1000 meters or more, and has been said to be a “phantom mushroom” because it is difficult to find. Until now, its cultivation has been difficult and generally not well known, but in recent years, an artificial cultivation method has been established and mass production has become possible.
本発明で用いられるハナビラタケ子実体は、その製造方法は特に限定されるものではなく、天然ものでも、人工栽培により得られたものであっても良い。人工栽培の方法としては、従来から知られている人工栽培用の菌床を作製することにより行なうことができる（詳細は、特開平１１−５６０９８号公報、特開２００２−３６９６２１号公報及び特開２００２−１２５４６０号公報、米国特許６，２１２，８２２などを参照）。 The manufacturing method of the fruit body used in the present invention is not particularly limited, and may be natural or artificially cultivated. Artificial cultivation can be performed by preparing a conventionally known fungal bed for artificial cultivation (for details, see Japanese Patent Application Laid-Open Nos. 11-56098, 2002-369621, and Japanese Patent Application Laid-Open No. 2002-369621). 2002-125460, US Pat. No. 6,212,822, etc.).
また、本発明で用いられるハナビラタケ菌糸体は、従来の液体培養法によって得ることができる。培地に使用する炭素源としては、グルコース等の単糖の他、デキストリン、グリセロール等、通常用いられる炭素源が使用できる。窒素源としては無機または有機窒素源が使用できるが、生育速度の観点からは有機窒素源を用いるほうが好ましい。また、必要に応じて微量元素やビタミン等の生育因子を添加することは通常の培養と何ら変わりはない。培養温度は１５℃〜３０℃、ｐＨは２．５〜８．０が好ましい。培地成分には不溶成分を添加することが均一に生育させることができることから好ましい。培養期間は菌株により、数日から数週間程度に設定されうる。 The mycelium mycelium used in the present invention can be obtained by a conventional liquid culture method. As the carbon source used in the medium, a commonly used carbon source such as dextrin and glycerol can be used in addition to a monosaccharide such as glucose. An inorganic or organic nitrogen source can be used as the nitrogen source, but it is preferable to use an organic nitrogen source from the viewpoint of the growth rate. Moreover, adding growth factors such as trace elements and vitamins as needed is no different from normal culture. The culture temperature is preferably 15 ° C to 30 ° C, and the pH is preferably 2.5 to 8.0. It is preferable to add an insoluble component to the medium component because it can be grown uniformly. The culture period can be set to several days to several weeks depending on the strain.
このようにして得られたハナビラタケ子実体又は菌糸体は次の抽出工程に移されるが、その際のハナビラタケの形態は特に限定されるものではなく、そのままの状態で、あるいは凍結乾燥物や乾燥物を微粉末化したものであっても良い。なかでも、乾燥物を微粉末化したものが抽出効率の点で好ましい。 The fruit body or mycelium obtained in this way is transferred to the next extraction step, but the form of the flower is not particularly limited, and is used as it is or in a freeze-dried product or a dried product. May be finely powdered. Among these, a powdered dry product is preferable from the viewpoint of extraction efficiency.
抽出工程で用いられる抽出溶媒としては、水、メタノール、エタノール、イソプロピルアルコール、ブタノール、グリセリン、エチレングリコール、１，３−ブチレングリコール、アセトン、クロロホルム、酢酸エチル、ヘキサン、エーテルなどが使用できる。これらの中で、水が好ましく、中でも熱水がさらに好ましい。熱水による抽出方法は特に限定されるものではなく、例えば、ハナビラタケ子実体又は菌糸体の乾燥粉末に５〜１００倍量の水を添加し、８０〜１００℃（高圧条件下では１００〜１２１℃）で２０分〜３時間、煮沸（加熱）する、あるいは、乾燥粉末に５〜１００倍量の水を添加し、１〜３時間加熱還流する。それら熱水抽出処理を数回繰り返す等、いかなる方法でも構わない。 As the extraction solvent used in the extraction step, water, methanol, ethanol, isopropyl alcohol, butanol, glycerin, ethylene glycol, 1,3-butylene glycol, acetone, chloroform, ethyl acetate, hexane, ether, or the like can be used. Among these, water is preferable, and hot water is more preferable. The extraction method using hot water is not particularly limited. For example, 5 to 100 times the amount of water is added to the dried powder of the fruit body or mycelia, and 80 to 100 ° C. (100 to 121 ° C. under high pressure conditions). ) Boil (heat) for 20 minutes to 3 hours, or add 5 to 100 times the amount of water to the dry powder and heat to reflux for 1 to 3 hours. Any method may be used such as repeating the hot water extraction treatment several times.
このようにして得られた溶媒抽出物には、分子量が５００〜１００００の範囲内の成分が含有されているので、この低分子量の成分を溶媒抽出物から分画すればよい。分画する方法は特に限定されないが、例えば、透析膜を用いる方法、ゲル濾過法あるいはエタノール沈澱による方法などが挙げられる。具体的には以下のようにして行うことができる。 Since the solvent extract thus obtained contains components having a molecular weight in the range of 500 to 10,000, this low molecular weight component may be fractionated from the solvent extract. The method of fractionation is not particularly limited, and examples thereof include a method using a dialysis membrane, a gel filtration method, and a method using ethanol precipitation. Specifically, it can be performed as follows.
上記のようにして得られた溶媒抽出物を一旦凍結乾燥処理により乾燥物とした後、適当量の水に再溶解し、分画分子量が５，０００〜１０，０００の範囲にある透析膜を用いて透析を行う。透析膜の具体例としては、フナコシ製、スペクトラバイオテックメンブレンシリーズ、スペクトラ／ポアＣＥシリーズ、同ＲＣシリーズ等が挙げられる。透析外液には蒸留水を用いれば良いが、溶媒抽出物の乾燥物より調製する透析内液は、乾燥物の溶解性に応じて酢酸ナトリウム、水酸化ナトリウムや尿素等を適宜添加する。透析外液（蒸留水）を入れた容器に透析外液を満たして、両端を厳重に密封した透析膜（チューブ）を浸漬し、１〜３日静置、あるいは攪拌下で放置する。これにより透析外液中に分子量が５００〜１００００の範囲内の成分が得られる。なお、透析工程を数回繰り返すことにより、透析外液画分の回収量を増やすことも可能である。 The solvent extract obtained as described above is once lyophilized to obtain a dried product, which is then redissolved in an appropriate amount of water, and a dialysis membrane having a fractional molecular weight in the range of 5,000 to 10,000 is obtained. Dialyze using. Specific examples of the dialysis membrane include Funakoshi, Spectra Biotech Membrane Series, Spectra / Pore CE Series, and RC Series. Distilled water may be used as the dialysis outer solution, but sodium acetate, sodium hydroxide, urea, or the like is appropriately added to the dialysis internal solution prepared from the dried product of the solvent extract depending on the solubility of the dried product. A dialysis membrane (tube) tightly sealed at both ends is immersed in a container filled with dialysis solution (distilled water), and left at 1 to 3 days or left under stirring. Thereby, a component having a molecular weight in the range of 500 to 10,000 is obtained in the dialysis external solution. In addition, it is also possible to increase the collection amount of the dialysis external liquid fraction by repeating the dialysis step several times.
ゲル濾過法による方法は、上記と同様にして得られた溶媒抽出物の乾燥物を適当な濃度に溶解し、ゲル濾過用の担体を充填したガラスカラムに通すことにより、分子量が５００〜１００００の範囲内の成分を得ることができる。ここで用いるカラム担体としては、アマシャムファルマシアバイオテク社のセファクリルシリーズ、セファデックスシリーズ等が挙げられる。 In the gel filtration method, the dried product of the solvent extract obtained in the same manner as described above is dissolved in an appropriate concentration and passed through a glass column packed with a carrier for gel filtration, so that the molecular weight is 500 to 10,000. Components in the range can be obtained. Examples of the column carrier used here include Sephacryl series and Sephadex series of Amersham Pharmacia Biotech.
エタノール沈殿の方法は、上記と同様にして得られた溶媒抽出物を、７５％エタノールに溶解し、不溶性の沈殿物を取除くことにより上澄液中に分子量が５００〜１００００の範囲内の成分を得ることができる。 In the ethanol precipitation method, a solvent extract obtained in the same manner as described above was dissolved in 75% ethanol, and the insoluble precipitate was removed to remove components in the supernatant having a molecular weight in the range of 500 to 10,000. Can be obtained.
このようにして得られた、分子量が５００〜１００００の範囲内、好ましくは分子量が２０００〜８０００の範囲内、さらに好ましくは分子量が４０００〜６０００の範囲内、最も好ましくは分子量が約５０００の成分を主成分とするハナビラタケ溶媒抽出物は、以下の実施例に示すように高い抗腫瘍活性を持つことが明らかになった。これは、本成分が低分子量であるために消化管からの吸収が促進された、あるいは腸管における免疫活性が向上したことによるものと考えられる。
なお、本発明において分子量は、ＧＰＣ法（カラム；ＵｌｔｒａｈｙｄｒｏｇｅｌＧｕａｒｄ＋１２０＋５００；Ｗａｔｅｒｓ製、移動相；０．５Ｍりん酸緩衝液（ｐＨ１１）、流速；０．５ｍＬ／分、検出；示差屈折率、推定分子量は各分子量のデキストランの保持時間より算出）により求めたものである。The component thus obtained has a molecular weight in the range of 500 to 10,000, preferably in the range of 2000 to 8000, more preferably in the range of 4000 to 6000, most preferably about 5000. As a result, it has been clarified that the Hanabiratake solvent extract as a main component has high antitumor activity as shown in the following examples. This is thought to be due to the fact that this component has a low molecular weight, so that absorption from the gastrointestinal tract is promoted or immune activity in the intestinal tract is improved.
In the present invention, the molecular weight is the GPC method (column; UltrahydroguardGuard + 120 + 500; manufactured by Waters, mobile phase; 0.5 M phosphate buffer (pH 11), flow rate: 0.5 mL / min, detection; differential refractive index, estimated molecular weight is Calculated from the retention time of molecular weight dextran).
本発明のハナビラタケ抽出物組成物の乾燥重量中、分子量５００〜１００００の範囲内の成分は、好ましくは８０重量％〜１００重量％、さらに好ましくは９０重量％〜１００重量％、最も好ましくは９５重量％〜１００重量％である。
また、本発明のハナビラタケ抽出物組成物は分子量が数百万程度のβグルカンをほとんど含有せず、本発明のハナビラタケ抽出物組成物の乾燥重量中、分子量が数百万程度のβグルカンの含有量は、５重量％以下、好ましくは、１重量％以下である。In the dry weight of the extract of the present invention, the components having a molecular weight in the range of 500 to 10,000 are preferably 80% to 100% by weight, more preferably 90% to 100% by weight, and most preferably 95% by weight. % To 100% by weight.
In addition, the garlic bamboo extract composition of the present invention contains almost no β-glucan having a molecular weight of about several million, and the dry weight of the garlic bamboo extract composition of the present invention contains β-glucan having a molecular weight of about several million. The amount is 5% by weight or less, preferably 1% by weight or less.
本発明の抗腫瘍性組成物、抗腫瘍剤、化粧品又は健康食品は、上記のようにして得られたハナビラタケ抽出物を有効成分として含有し、さらに製薬的に許容される担体、化粧用として許容される担体、又は、健康食品として許容される食品及び／または飲料を含有するものである。ハナビラタケ抽出物の含有量としては、ハナビラタケが食経験のある極めて安全なキノコであることから、特に限定されるものではないが、概ね、下限は予防または治療といった目的に応じた効果を発揮する量を、上限は服用のし易さ、経済性等の観点から実際的な量を基準とし、原料であるハナビラタケ子実体又は菌糸体の乾燥重量に換算して、成人１日あたり５ｍｇ〜５００ｇ、好ましくは５０ｍｇ〜５０ｇを摂取できるように含有量及び摂取量を設定すればよい。投与量は、本発明の組成物としては、乾燥重量に換算して、成人１日あたり０．２５ｍｇ〜２．５ｇ、好ましくは２．５ｍｇ〜２．５ｇを摂取できるように含有量及び摂取量を設定すればよい。本発明の抗腫瘍剤、化粧品、又は健康食品は、その形態は特に限定されるものではなく、錠剤状、カプセル状、粉末状、顆粒状、液状、懸濁液状、クリーム状等、あらゆる形態で利用できる。
本発明の抗腫瘍剤には製薬的に許容できる種々の担体を加えることができる。例えば、賦形剤、結合剤、崩壊剤、滑沢剤、着香剤、着色剤、甘味剤、矯味剤、溶解補助剤、懸濁化剤、乳化剤、コーティング剤を含むことができるが、これらに限定されない。本発明のハナビラタケ溶媒抽出物組成物を持続性、徐放性のものとしてもよい。
本発明の化粧料は、化粧品、医薬部外品、医薬品に用いられる水性成分、油性成分、植物抽出液、動物抽出液、粉末、界面活性剤、油剤、アルコール、ｐＨ調整剤、防腐剤、酸化防止剤、増粘剤、色素、香料等を必要に応じて適宜配合することにより調整される。さらに本発明の化粧料は、上記したもののほかに、美白剤、保湿剤、抗炎症剤、紫外線吸収剤等、他の有効成分を含ませるものであってもよい。
本発明の健康食品は、本発明のハナビラタケ溶媒抽出物組成物を飲食品の原材料に前記の配合量となるよう配合することにより、麺類、パン、キャンディー、ゼリー、クッキー、スープの形態とすることができる。さらに、鉄、カルシウム等の無機成分、種々のビタミン類、オリゴ糖、キトサン等の食物繊維、大豆抽出物等のタンパク質、レシチンなどの脂質、ショ糖、乳糖等の糖類を加えることもできる。
本発明の、ハナビラタケ抽出物の投与対象はその効果が発揮される限り特に限定されないが、好ましくは、温血動物であり、さらに好ましくは哺乳類であり、最も好ましくはヒトである。The antitumor composition, antitumor agent, cosmetic or health food of the present invention contains the extract of Hanabira bamboo obtained as described above as an active ingredient, and is further pharmaceutically acceptable carrier and cosmetically acceptable. Or a food and / or beverage acceptable as a health food. The content of the extract is not particularly limited because it is an extremely safe mushroom with food experience, but the lower limit is generally an amount that exerts an effect according to the purpose of prevention or treatment. The upper limit is 5 mg to 500 g per day for adults, preferably in terms of the dry weight of the fruit body or mycelium that is the raw material, based on the practical amount from the viewpoint of ease of taking, economy, etc. Should just set content and intake so that 50 mg-50 g can be ingested. As for the composition of the present invention, the content and the intake amount so that the adult can ingest 0.25 mg to 2.5 g, preferably 2.5 mg to 2.5 g per day, in terms of dry weight. Should be set. The form of the antitumor agent, cosmetic or health food of the present invention is not particularly limited, and it can be in any form such as tablets, capsules, powders, granules, liquids, suspensions, creams, etc. Available.
Various carriers that are pharmaceutically acceptable can be added to the antitumor agent of the present invention. For example, excipients, binders, disintegrants, lubricants, flavoring agents, coloring agents, sweeteners, corrigents, solubilizers, suspending agents, emulsifiers, coating agents can be included. It is not limited to. It is good also as a long-lasting and sustained-release thing for the Hanabira bamboo solvent extract composition of this invention.
Cosmetics of the present invention are cosmetics, quasi drugs, aqueous components used in pharmaceuticals, oily components, plant extracts, animal extracts, powders, surfactants, oils, alcohols, pH adjusters, preservatives, oxidation It adjusts by mix | blending an inhibitor, a thickener, a pigment | dye, a fragrance | flavor, etc. suitably as needed. Furthermore, the cosmetic of the present invention may contain other active ingredients such as a whitening agent, a moisturizing agent, an anti-inflammatory agent, and an ultraviolet absorber in addition to the above.
The health food of the present invention is made into the form of noodles, bread, candy, jelly, cookies, soup by blending the extract of the solvent extract of the present invention into the raw materials of food and drink so as to have the above blending amount. Can do. Furthermore, inorganic components such as iron and calcium, various vitamins, dietary fibers such as oligosaccharides and chitosan, proteins such as soybean extract, lipids such as lecithin, saccharides such as sucrose and lactose can also be added.
The subject of the present invention is not particularly limited as long as its effect is exerted, but is preferably a warm-blooded animal, more preferably a mammal, and most preferably a human.
以下、実施例により本発明を詳細に説明するが、これらは本発明を何ら限定するものではない。 EXAMPLES Hereinafter, although an Example demonstrates this invention in detail, these do not limit this invention at all.
製造例１〔ハナビラタケ子実体の製造〕
ハナビラタケ子実体を以下の方法により製造した。
カラマツの大鋸屑、小麦粉、栄養分（バナナ、蜂蜜、エビオス、ペプトン、塩化カルシウム、ハイポネックス）および水を、大鋸屑：小麦粉：栄養分：水＝１００：１１．５：１．９：５１の重量比で含む菌床基材を準備した。この菌床基材（５２０ｇ）を８５０ｃｃのポリプロピレン製の培養瓶に入れ、常法にしたがって培養瓶を滅菌した後、ハナビラタケの種菌（１６ｇ）を接種した。その後、この培養瓶を２３℃の温度下、５６日間培養することによりハナビラタケ子実体を収穫した。子実体の重量は培養瓶１本あたり１４０ｇであった。Production Example 1 [Manufacture of Hanabiratake fruit body]
Hanabira bamboo fruit bodies were produced by the following method.
Bacteria containing larch sawdust, flour, nutrients (bananas, honey, prawns, peptone, calcium chloride, hyponex) and water in a weight ratio of sawdust: flour: nutrients: water = 100: 11.5: 1.9: 51 A floor substrate was prepared. This fungus bed base material (520 g) was placed in an 850 cc polypropylene culture bottle, and the culture bottle was sterilized according to a conventional method, followed by inoculation with seeds of Hanabiratake (16 g). Thereafter, the fruit bodies of the bamboo leaf were harvested by culturing the culture bottle at a temperature of 23 ° C. for 56 days. The weight of the fruiting body was 140 g per culture bottle.
製造例２〔ハナビラタケ菌糸体の製造〕
ハナビラタケ菌糸体を以下の方法により製造した。
イーストエキス０．４％、グルコース２％、りん酸２水素カリウム０．１％、りん酸水素２ナトリウム０．１％となるように水に溶解し、１Ｎの塩化水素でｐＨ５．０に調整した培地を５００ｍＬ容三角フラスコに２００ｍＬ入れ、常法にしたがって滅菌した。ハナビラタケの種菌を生育させた平板培地から径６ｍｍの寒天片を打ち抜き、この液体培地に接種した。２４℃の暗黒下、２１日間振とう培養することによりハナビラタケ菌糸体を収穫した。菌糸体の乾燥重量は三角フラスコ１本あたり２ｇであった。Production Example 2 [Manufacture of agaric mycelium]
Hanabiratake mycelium was produced by the following method.
Yeast extract 0.4%, glucose 2%, potassium dihydrogen phosphate 0.1%, disodium hydrogen phosphate 0.1% dissolved in water and adjusted to pH 5.0 with
実施例１〔ハナビラタケ子実体低分子抗腫瘍成分の調製〕
上記の製造例１で得られたハナビラタケ子実体の乾燥物をブレンダーで粉末とし、そのうち５０ｇに水２Ｌを加え、１００℃、２時間の抽出処理を行なった。遠心分離により上澄みを回収し、沈澱物について同様の抽出操作をさらに２回繰り返した。回収した上澄みを凍結乾燥し、抽出物２３ｇ（ハナビラタケ子実体熱水抽出物；ＳＣＦＨＥｘとする）を得た。抽出物を再び５００ｍＬの水に溶解し、分子量８０００カットの透析膜（フナコシ製、スペクトラバイオテックメンブレン ポア１．１）により透析を行なった。透析外液を回収し、凍結乾燥によりハナビラタケ子実体低分子抗腫瘍成分２．３ｇ（ＳＣＦＨＬとする）を得た。Example 1 [Preparation of Hanabiratake fruiting body small molecule antitumor component]
The dried product of the fruit of the bamboo shoot obtained in Production Example 1 was powdered with a blender, 2 L of water was added to 50 g, and an extraction treatment was performed at 100 ° C. for 2 hours. The supernatant was collected by centrifugation, and the same extraction operation was further repeated twice for the precipitate. The collected supernatant was freeze-dried to obtain 23 g of extract (Hanaburatake fruiting body hot water extract; referred to as SCFHEx). The extract was dissolved again in 500 mL of water and dialyzed with a dialysis membrane having a molecular weight of 8000 cut (Funakoshi, Spectra Biotech Membrane Pore 1.1). The dialyzed external solution was collected, and 2.3 g (referred to as SCFHL) of a low molecular weight anti-tumor component of Hanabiratake fruit body was obtained by lyophilization.
実施例２〔ハナビラタケ菌糸体低分子抗腫瘍成分の調製〕
上記の製造例２で得られたハナビラタケ菌糸体の乾燥物をブレンダーで粉末とし、そのうち５ｇに水２００ｍＬを加え、１００℃、１時間の抽出処理を行なった。遠心分離により回収した上澄みを凍結乾燥し、抽出物１．６ｇ（ハナビラタケ菌糸体熱水抽出物；ＳＣＭＨＥｘとする）を得た。抽出物を再び２００ｍＬの水に溶解し、分子量８０００カットの透析膜（フナコシ製、スペクトラバイオテックメンブレン ポア１．１）により透析を行なった。透析外液を回収し、凍結乾燥によりハナビラタケ菌糸体低分子抗腫瘍成分０．６２ｇ（ＳＣＭＨＬとする）を得た。Example 2 [Preparation of low-molecular weight anti-tumor component of Mytilus mycelium]
The dried material of the agaric mycelium obtained in Production Example 2 was powdered with a blender, 200 mL of water was added to 5 g of the dried product, and an extraction treatment was performed at 100 ° C. for 1 hour. The supernatant collected by centrifugation was freeze-dried to obtain 1.6 g of extract (Hanabiratake mycelium hot water extract; referred to as SCMHEx). The extract was dissolved again in 200 mL of water, and dialyzed with a dialysis membrane having a molecular weight of 8000 cut (Funakoshi, Spectra Biotech Membrane Pore 1.1). The dialyzed external solution was collected, and 0.62 g (referred to as SCMHL) of the low molecular weight anti-tumor component of the fly mycelia mycelia was obtained by lyophilization.
実施例３〔ハナビラタケ子実体低分子抗腫瘍成分の調製２〕
上記の製造例１で得られたハナビラタケ子実体の乾燥物をブレンダーで粉末とし、そのうち５０ｇに水２Ｌを加え、１００℃、２時間の抽出処理を行なった。遠心分離により上澄みを回収し、沈澱物について同様の抽出操作をさらに２回繰り返した。回収した上澄みを凍結乾燥し、得られた抽出物のうち１ｇを５０ｍＬの水に溶解し、セファデックスＧ−７５のゲル濾過担体を充填したカラム（φ３０ｍｍ×９００ｍｍ、充填量５００ｍＬ）に流速２００ｍｍ／時でアプライし、引き続き蒸留水により展開を行なった。５０ｍＬずつ分画分取しＧＰＣ法（カラム；ＵｌｔｒａｈｙｄｒｏｇｅｌＧｕａｒｄ＋１２０＋５００；Ｗａｔｅｒｓ製、移動相；０．５Ｍりん酸緩衝液（ｐＨ１１）、流速；０．５ｍＬ／分、検出；示差屈折率、推定分子量は各分子量のデキストランの保持時間より算出）により分子量を確認し、分子量５００以上、１００００以下の各分を回収し、凍結乾燥によりハナビラタケ子実体低分子抗腫瘍成分０．０７６ｇを得た。Example 3 [Preparation 2 of small-sized anti-tumor component of Hanabiratake fruit body]
The dried product of the fruit of the bamboo shoot obtained in Production Example 1 was powdered with a blender, 2 L of water was added to 50 g, and an extraction treatment was performed at 100 ° C. for 2 hours. The supernatant was collected by centrifugation, and the same extraction operation was further repeated twice for the precipitate. The collected supernatant was freeze-dried, 1 g of the obtained extract was dissolved in 50 mL of water, and a flow rate of 200 mm / mm was applied to a column (φ30 mm × 900 mm, packing amount 500 mL) packed with Sephadex G-75 gel filtration carrier. It was applied at the same time and subsequently developed with distilled water. 50 mL fractions were collected and the GPC method (column; UltrahydroGuard + 120 + 500; manufactured by Waters, mobile phase; 0.5 M phosphate buffer (pH 11), flow rate: 0.5 mL / min, detection; differential refractive index, estimated molecular weight for each molecular weight The molecular weight was determined by calculating from the retention time of dextran, and each part having a molecular weight of 500 or more and 10,000 or less was collected, and 0.076 g of a small-sized antitumor component of Hanabiratake fruiting body was obtained by lyophilization.
比較例１〔アガリクスタケ子実体低分子抗腫瘍成分の調製〕
アガリクスタケ子実体の乾燥物をブレンダーで粉末とし、そのうち３６ｇに水２Ｌを加え、１００℃、２時間の抽出処理を行なった。遠心分離により上澄みを回収し、沈澱物について同様の抽出操作をさらに２回繰り返した。回収した上澄みを凍結乾燥し、抽出物２５ｇを得た。抽出物を再び５００ｍＬの水に溶解し、分子量８０００カットの透析膜（フナコシ製、スペクトラバイオテックメンブレン ポア１．１）により透析を行なった。透析外液を回収し、凍結乾燥によりアガリクスタケ子実体低分子抗腫瘍成分１０．９ｇ（ＡＢＦＨＬ）を得た。Comparative Example 1 [Preparation of small body anti-tumor component of Agaricusutake fruit body]
The dried product of Agaricus stadium fruit body was powdered with a blender, and 2 L of water was added to 36 g, and extraction treatment was performed at 100 ° C. for 2 hours. The supernatant was collected by centrifugation, and the same extraction operation was further repeated twice for the precipitate. The collected supernatant was freeze-dried to obtain 25 g of an extract. The extract was dissolved again in 500 mL of water and dialyzed with a dialysis membrane having a molecular weight of 8000 cut (Funakoshi, Spectra Biotech Membrane Pore 1.1). The dialyzed external solution was collected and freeze-dried to obtain 10.9 g (ABFHL) of Agaricustake fruit body small molecule antitumor component.
試験例１〔βグルカンの定量〕
実施例１、２にしたがって調製したハナビラタケ熱水抽出物（ＳＣＦＨＥｘ、ＳＣＭＨＥｘ）、ハナビラタケ低分子抗腫瘍成分（ＳＣＦＨＬ、ＳＣＭＨＬ）について、コンゴーレッド法によるβグルカン量の定量を行なった。それぞれの２％水溶液を調製し、コンゴーレッド試薬を用いてβグルカンの定量を行なったところ、ＳＣＦＥｘは５ｍｇ／ｍＬ（２５％対固形分）、ＳＣＭＥｘは１ｍｇ／ｍＬ（５％対固形分）のβグルカンが検出されたのに対し、分画処理して得られた低分子成分であるＳＣＦＨＬには０．０８ｍｇ／ｍＬ（０．４％対固形分）以下、ＳＣＭＨＬには０．０３ｍｇ／ｍＬ（０．２％対固形分）以下のβグルカンしか検出されなかった。Test Example 1 [Quantification of β-glucan]
The amount of β-glucan was quantified by Congo red method for the hot water extract (SCFHEx, SCMHEx) and the low molecular weight antitumor component (SCFHL, SCMHL) prepared according to Examples 1 and 2. Each 2% aqueous solution was prepared, and β-glucan was quantified using Congo red reagent. SCFEx was 5 mg / mL (25% vs. solid content), SCMEx was 1 mg / mL (5% vs. solid content). β-glucan was detected, whereas SCFHL, which is a low molecular component obtained by fractionation, was 0.08 mg / mL (0.4% solids) or less, and SCMHL was 0.03 mg / mL. Only β-glucan below (0.2% solids) was detected.
なお、コンゴーレッド法によって定量されるβグルカンは、分子量が１０万以上のものといわれる。 Note that β-glucan quantified by the Congo Red method is said to have a molecular weight of 100,000 or more.
このことから、ＳＣＦＥｘ、ＳＣＭＥｘに含まれていたβグルカン（分子量数万〜数十万）は透析膜による分画処理によって９６％以上が除去され、ＳＣＦＨＬ、ＳＣＭＨＬにはほとんど含まれないことが明らかになった。また、コンゴーレッドのメタクロマジー（色調の変化、吸収極大のシフト）（特開２０００−２１７５４３号公報参照）も、ＳＣＦＨＬ、ＳＣＭＨＬでは認められなかった。 From this, it is clear that 96% or more of β-glucan (molecular weight tens of thousands to several hundreds of thousands) contained in SCFEx and SCMEx is removed by fractionation treatment with a dialysis membrane, and is hardly contained in SCFHL and SCMHL. Became. Also, Congo red metachromy (change in color tone, shift in absorption maximum) (see JP 2000-217543 A) was not observed in SCFHL and SCMHL.
試験例２〔分子量分布の確認１〕
実施例１に従って調製したハナビラタケ子実体熱水抽出物（ＳＣＦＨＥｘ）、ハナビラタケ子実体低分子抗腫瘍成分（ＳＣＦＨＬ）の分子量分布をＧＰＣ法（前記）により確認したところ、熱水抽出物のメインピークは５万前後の分子量を示したのに対し、低分子抗腫瘍成分は５０００前後であった。チャートを図１に示した。Test Example 2 [Confirmation 1 of molecular weight distribution]
As a result of confirming the molecular weight distribution of Hanabiratake fruit body hot water extract (SCFHEx) and Hanabiratake fruit body low molecular weight antitumor component (SCFHL) prepared according to Example 1, the main peak of the hot water extract is While the molecular weight was around 50,000, the low molecular weight antitumor component was around 5000. The chart is shown in FIG.
試験例３〔分子量分布の確認２〕
実施例２に従って調製したハナビラタケ菌糸体熱水抽出物（ＳＣＭＨＥｘ）、ハナビラタケ菌糸体低分子抗腫瘍成分（ＳＣＭＨＬ）の分子量分布をＧＰＣ法（前記）により確認したところ、熱水抽出物のメインピークは５万前後の分子量を示したのに対し、低分子抗腫瘍成分は５０００前後であった。Test Example 3 [Confirmation of molecular weight distribution 2]
As a result of confirming the molecular weight distribution of Hanabiratake mycelium hot water extract (SCMHEX) and Hanabiratake mycelium low molecular weight antitumor component (SCMHL) prepared according to Example 2, the main peak of the hot water extract is While the molecular weight was around 50,000, the low molecular weight antitumor component was around 5000.
試験例４〔がん細胞の増殖抑制試験〕
実施例１、２で調製したハナビラタケ子実体熱水抽出物（ＳＣＦＨＥｘ）、ハナビラタケ菌糸体熱水抽出物（ＳＣＭＨＥｘ）、ハナビラタケ子実体低分子抗腫瘍成分（ＳＣＦＨＬ）、ハナビラタケ菌糸体低分子抗腫瘍成分（ＳＣＭＨＬ）、比較例１で調製したアガリクスタケ子実体低分子抗腫瘍成分（ＡＢＦＨＬ）をりん酸バッファー（ＰＢＳ、ｐＨ７．２）に溶解し、それぞれ１０ｍｇ／ｍＬの濃度に調整した。ヒト大腸がん細胞（Ｃａｃｏ−２）、あるいは、ヒト白血病細胞（ＨＬ−６０）をＲＰＭＩ１６４０−１０％ウシ血清培地（ｐＨ７．２）に６００００個／ｍＬの濃度となるように懸濁し、９０μＬずつ９６穴プレートに分注した。上記試料をそれぞれ１０μＬずつ（ブランクにはＰＢＳのみを１０μＬ、ポジティブコントロールにはアクチノマイシンＤを１μｇ／ｍＬの濃度に調整したものを１０μＬ）分注し、よく混和した後、５％炭酸ガス雰囲気下、３７℃で４８〜７２時間培養し、生細胞数をＣｅｌｌＣｏｕｎｔｉｎｇＫｉｔ８（同仁化学研究所製）で計測し、ブランクの細胞増殖量と比較して、細胞増殖抑制率を算出した。Test Example 4 [Cancer Cell Growth Inhibition Test]
Hanabiratake fruit body hot water extract (SCFHEx), Hanabiratake mycelium hot water extract (SCMHEEx), Hanabiratake fruit body small molecule antitumor component (SCFHL), Hanabiratake mycelium small molecule antitumor component prepared in Examples 1 and 2 (SCMHL), Agaricustake fruit body small molecule antitumor component (ABFHL) prepared in Comparative Example 1 was dissolved in phosphate buffer (PBS, pH 7.2) and adjusted to a concentration of 10 mg / mL. Human colon cancer cells (Caco-2) or human leukemia cells (HL-60) are suspended in RPMI 1640-10% bovine serum medium (pH 7.2) to a concentration of 60,000 cells / mL, and 90 μL each. Dispense into 96-well plates. Dispense 10 μL each of the above samples (10 μL of PBS alone for the blank and 10 μL of the actinomycin D adjusted to a concentration of 1 μg / mL for the positive control), mix well, and then in a 5% carbon dioxide atmosphere The cells were cultured at 37 ° C. for 48 to 72 hours, the number of viable cells was measured with CellCounting Kit 8 (manufactured by Dojindo Laboratories), and the cell growth inhibition rate was calculated by comparison with the blank cell growth amount.
結果を表１に示した。 The results are shown in Table 1.
表１の結果から明らかなように、本発明のハナビラタケ低分子抗腫瘍成分は、がん細胞の増殖を抑制する効果を示し、その強度は単なる熱水抽出物と比べると有意に高くなっており、透析膜による分画が、がん細胞の増殖抑制効果を発揮するのに有効であることが明らかになった。 As is clear from the results of Table 1, the low molecular weight anti-tumor component of the present invention exhibits an effect of suppressing the growth of cancer cells, and its strength is significantly higher than that of a mere hot water extract. It was revealed that fractionation using a dialysis membrane is effective for exerting an inhibitory effect on the growth of cancer cells.
試験例５〔経口摂取による腫瘍増殖抑制試験〕
マウス（ＩＣＲ：Ｊｃｌ、６週齢、メス、１０匹／群）の右上肢腋下部に、Ｅ・ＭＥＭ無血清培地（ｐＨ７．２）に４０００００００個／ｍＬの濃度となるように懸濁したマウス肉腫細胞（Ｓ１８０）を５０μＬずつ移植した。移植日より７日目から１０日間、実施例１，２及び比較例１にしたがって調製したハナビラタケ子実体低分子抗腫瘍成分（ＳＣＦＨＬ）、ハナビラタケ菌糸体低分子抗腫瘍成分（ＳＣＭＨＬ）、アガリクスタケ子実体低分子抗腫瘍成分（ＡＢＦＨＬ）、ならびに、ハナビラタケ熱水抽出物（ＳＣＦＨＥｘ、ＳＣＭＨＥｘ）の水溶液（濃度；１８ｍｇ／ｍＬ）を５０μＬずつ（ブランクには水道水を５０μＬ）経口投与した（体重１Ｋｇあたり３０ｍｇ投与）。移植日より３５日間、３、４日おきに腫瘍サイズの計測を行ない経時変化を観察すると共に、最終日に腫瘍塊を摘出し、その重量より腫瘍増殖抑制率を算出した。腫瘍サイズはその長径×短径×短径÷２の計算式より算出した。Test Example 5 [Tumor Growth Inhibition Test by Ingestion]
A mouse (ICR: Jcl, 6 weeks old, female, 10 mice / group) suspended in an E.MEM serum-free medium (pH 7.2) at a concentration of 40000000 / mL at the lower right limbs Sarcoma cells (S180) were transplanted at 50 μL each. Hanabiratake fruit body small molecule antitumor component (SCFHL), Hanabiratake mycelium small molecule antitumor component (SCMHL), Agaricustake fruit body prepared from Examples 1 and 2 and Comparative Example 1 for 7 days from the day of transplantation An aqueous solution (concentration: 18 mg / mL) of a low molecular weight antitumor component (ABFHL) and an extract of hot water bamboo (SCFHEx, SCMHEEx) was orally administered at 50 μL each (50 μL of tap water in the blank) (30 mg per 1 kg body weight) Administration). The tumor size was measured every 35 days, 3 days, and 4 days from the date of transplantation, the change with time was observed, and the tumor mass was excised on the final day, and the tumor growth inhibition rate was calculated from its weight. The tumor size was calculated from the formula of its major axis × minor axis × minor axis ÷ 2.
結果を図２、表２に示した。 The results are shown in FIG.
図２、表２の結果から明らかなように、本発明のハナビラタケ低分子抗腫瘍成分は、がん細胞の増殖を抑制する効果を示し、その強度は単なる熱水抽出物と比べると、それぞれ１０％程度高くなっており、透析膜による分画が、がん細胞の増殖抑制効果を発揮するのに有効であることが明らかになった。
本発明を詳細にまた特定の実施態様を参照して説明したが、本発明の精神と範囲を逸脱することなく様々な変更や修正を加えることができることは当業者にとって明らかである。
本出願は、２００５年５月２５日出願の日本特許出願（特願２００５−１５２４５４）に基づくものであり、その内容はここに参照として取り込まれる。As is apparent from the results in FIG. 2 and Table 2, the low-molecular weight anti-tumor component of the present invention shows an effect of suppressing the growth of cancer cells, and its strength is 10 respectively compared with a simple hot water extract. It was revealed that fractionation with a dialysis membrane is effective for exerting a cancer cell growth inhibitory effect.
Although the present invention has been described in detail and with reference to specific embodiments, it will be apparent to those skilled in the art that various changes and modifications can be made without departing from the spirit and scope of the invention.
This application is based on a Japanese patent application filed on May 25, 2005 (Japanese Patent Application No. 2005-152454), the contents of which are incorporated herein by reference.
本発明は、ハナビラタケの子実体又は菌糸体から得られる比較的低分子量の成分を主成分とするハナビラタケ抽出物並びにそれを有効成分として含有する抗腫瘍剤、化粧品及び健康食品を提供する。 The present invention provides an extract of Hanabira bamboo mainly composed of a relatively low molecular weight component obtained from the fruit body or mycelium of Hanabira bamboo, and an antitumor agent, a cosmetic and a health food containing the same as an active ingredient.
Claims (11)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2005152454 | 2005-05-25 | ||
| JP2005152454 | 2005-05-25 | ||
| PCT/JP2006/310151 WO2006126488A1 (en) | 2005-05-25 | 2006-05-22 | Cauliflower mushroom extract |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| JPWO2006126488A1 true JPWO2006126488A1 (en) | 2008-12-25 |
Family
ID=37451914
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2007517815A Pending JPWO2006126488A1 (en) | 2005-05-25 | 2006-05-22 | Hanabira bamboo extract |
Country Status (2)
| Country | Link |
|---|---|
| JP (1) | JPWO2006126488A1 (en) |
| WO (1) | WO2006126488A1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP5063040B2 (en) * | 2006-06-30 | 2012-10-31 | ユニチカ株式会社 | Angiogenesis inhibitor |
| JP5658479B2 (en) * | 2009-04-27 | 2015-01-28 | 株式会社岩出菌学研究所 | Composition showing activity such as fat reduction |
| WO2018168879A1 (en) * | 2017-03-13 | 2018-09-20 | 学校法人東京女子医科大学 | Composition having estrogen-like action, medicine, food and beverage containing same, method for producing composition having estrogen-like action and method for utilizing dna base sequence of sparassis crispa |
Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10298099A (en) * | 1997-04-23 | 1998-11-10 | Kozo Niwa | Cell-activating composition |
| JP2000159808A (en) * | 1998-11-27 | 2000-06-13 | Kobayashi Pharmaceut Co Ltd | Method for separating and purifying basidiomycota hypha extract |
| JP2000217543A (en) * | 1999-01-29 | 2000-08-08 | Nakajima Mitsuhiro | SPARASSIS CRISPA Fr. EXTRACT |
| WO2001051070A1 (en) * | 2000-01-12 | 2001-07-19 | Life Science Laboratories Co., Ltd. | Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs |
| WO2003051382A1 (en) * | 2001-12-14 | 2003-06-26 | Sundory Co., Ltd. | Method of inducing apoptosis and compositions therefor |
| JP2004350620A (en) * | 2003-05-30 | 2004-12-16 | Unitika Ltd | Zinc replenishing food material |
-
2006
- 2006-05-22 WO PCT/JP2006/310151 patent/WO2006126488A1/en active Application Filing
- 2006-05-22 JP JP2007517815A patent/JPWO2006126488A1/en active Pending
Patent Citations (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPH10298099A (en) * | 1997-04-23 | 1998-11-10 | Kozo Niwa | Cell-activating composition |
| JP2000159808A (en) * | 1998-11-27 | 2000-06-13 | Kobayashi Pharmaceut Co Ltd | Method for separating and purifying basidiomycota hypha extract |
| JP2000217543A (en) * | 1999-01-29 | 2000-08-08 | Nakajima Mitsuhiro | SPARASSIS CRISPA Fr. EXTRACT |
| WO2001051070A1 (en) * | 2000-01-12 | 2001-07-19 | Life Science Laboratories Co., Ltd. | Physiologically active substance eem-s originating in mushrooms, process for producing the same and drugs |
| WO2003051382A1 (en) * | 2001-12-14 | 2003-06-26 | Sundory Co., Ltd. | Method of inducing apoptosis and compositions therefor |
| JP2004350620A (en) * | 2003-05-30 | 2004-12-16 | Unitika Ltd | Zinc replenishing food material |
Also Published As
| Publication number | Publication date |
|---|---|
| WO2006126488A1 (en) | 2006-11-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CN108289422B (en) | Method for producing mushroom | |
| Ślusarczyk et al. | Fungi and algae as sources of medicinal and other biologically active compounds: A review | |
| WO2017008768A1 (en) | Glucan and preparation method thereof, and application in preparation of immune-enhancing and antitumor medicine and functional food | |
| CN105641000A (en) | Antitumor composition containing grifola frondosus extract and preparation method thereof | |
| Chandrasekaran et al. | Properties and potential applications of the culinary-medicinal cauliflower mushroom, Sparassis crispa Wulf.: Fr.(Aphyllophoromycetideae): a review | |
| TWI724352B (en) | Polysaccharide fermentation compositioncapable of anti-cancer, anti-virus, anti-inflammatory, promoting osteoblast proliferation, promoting intestinal stem cell proliferation effects and preparation method thereof. | |
| WA et al. | Bioactive potential of some fascinating edible mushrooms Macrolepiota, Russula, Amanita, Vovariella and Grifola as a treasure of multipurpose therapeutic natural product | |
| JP2004315512A (en) | Functional composition | |
| JPWO2006126488A1 (en) | Hanabira bamboo extract | |
| KR100340663B1 (en) | A method of preparing the antitumor and immuno-activity polysaccharide from the artificial cultivation of inonotus obliquus, and its use | |
| JP4451100B2 (en) | Immunostimulant and anticancer agent containing Tamogitake fruit body composition as active ingredient | |
| JP5063040B2 (en) | Angiogenesis inhibitor | |
| JP2009143854A (en) | Wound-healing promoter | |
| JPH11302191A (en) | Immunoactivator and antitumor agent containing extract from lyophyllum decastes (fr.) sing. as active ingredient | |
| CA2523895A1 (en) | Basidiomycetes, basidiomycetes extract composition, health foods and immunopotentiators | |
| KR101768817B1 (en) | Food composition for anti-oxidation and inhanced immunity comprising chamomile flower extract short-term fermented by lactic acid bacteria and the method of preparation thereof | |
| KR100729213B1 (en) | Exo-biopolymer isolated from submerged mycelial culture of Grifola frondosa increasing immune activity | |
| JPWO2008084574A1 (en) | Angiogenesis inhibitor | |
| JP2005281224A (en) | Skin-whitening agent | |
| JP2007031314A (en) | Composition having ameliorating action on allergic symptom | |
| KR20030072417A (en) | Manufacture method of a functional tea and food, using extract of mushroom mycelium by new extraction technique. | |
| KR20200084215A (en) | Anti-inflammatory composition comprising extract of Polyopes affinis | |
| KR101755338B1 (en) | Process for preparation of grifola frondosa fruit body with twice fermentation and functional grifola frondosa fruit body fermentative products | |
| Ślusarczyk et al. | Fungi and Algae as Sources of Medicinal and Other Biologically Active Com-pounds: A Review. Nutrients 2021, 13, 3178 | |
| JP2006137680A (en) | Collagen production-promoting agent |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20090319 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120221 |
|
| A521 | Written amendment |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20120417 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20120515 |
|
| A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20121106 |